- One Health
- Pain Management
- Oncology
- Geriatric & Palliative Medicine
- Ophthalmology
- Anatomic Pathology
- Poultry Medicine
- Infectious Diseases
- Dermatology
- Theriogenology
- Nutrition
- Animal Welfare
- Radiology
- Internal Medicine
- Small Ruminant
- Cardiology
- Dentistry
- Feline Medicine
- Soft Tissue Surgery
- Urology/Nephrology
- Avian & Exotic
- Preventive Medicine
- Anesthesiology & Pain Management
- Integrative & Holistic Medicine
- Food Animals
- Behavior
- Zoo Medicine
- Toxicology
- Orthopedics
- Emergency & Critical Care
- Equine Medicine
- Pharmacology
- Pediatrics
- Respiratory Medicine
- Shelter Medicine
- Parasitology
- Clinical Pathology
- Virtual Care
- Rehabilitation
- Epidemiology
- Fish Medicine
- Diabetes
- Livestock
- Endocrinology
Schering-Plough transfers products in European market
Kenilworth, N.J. -- Schering-Plough Corp announced last month that it was closing on its transfer of certain products to Pfizer Animal Health.
Kenilworth, N.J.
-- Schering-Plough Corp announced last month that it was closing on its transfer of certain products to Pfizer Animal Health.
The transfers were requested by the European Commission as part of an October 2007 clearance of the acquisition of Oraganon BioSciences N.V. by Pfizer.
Products transferred to Pfizer in the European market include products from Schering-Plough's parasiticide, swine E. coli vaccine, ruminant clostridia vaccine, equine influenza vaccine, ruminant neonatal vaccine, anti-inflammatory companion animal/insulin and companion animal/euthanasia and rabies vaccine franchises, according to Schering-Plough.
Schering-Plough still will be able to market those items outside of the European market, according to the company.
